Equities

MoonLake Immunotherapeutics

MLTX:NAQ

MoonLake Immunotherapeutics

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)54.09
  • Today's Change2.23 / 4.30%
  • Shares traded142.04k
  • 1 Year change+19.38%
  • Beta1.2857
Data delayed at least 15 minutes, as of Nov 22 2024 20:24 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy8
Outperform5
Hold4
Sell0
Strong Sell0

Share price forecast in USD

The 13 analysts offering 12 month price targets for MoonLake Immunotherapeutics have a median target of 72.00, with a high estimate of 104.00 and a low estimate of 55.00. The median estimate represents a 38.84% increase from the last price of 51.86.
High100.5%104.00
Med38.8%72.00
Low6.1%55.00

Earnings history & estimates in USD

On Nov 07, 2024, MoonLake Immunotherapeutics reported 3rd quarter 2024 losses of -0.56 per share.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate-42.72%
MoonLake Immunotherapeutics reported annual 2023 losses of -0.73 per share on Feb 29, 2024.
Average growth rate+57.06%
More ▼

Revenue history & estimates in USD

MoonLake Immunotherapeutics did not report revenues for the 3rd quarter 2024. However, during the 3rd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
MoonLake Immunotherapeutics did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.